Literature DB >> 9205223

Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: value of dynamic contrast-enhanced subtraction MR imaging.

K Kinkel1, M Ariche, A A Tardivon, A Spatz, D Castaigne, C Lhomme, D Vanel.   

Abstract

PURPOSE: To compare dynamic contrast material-enhanced subtraction and T2-weighted spin-echo (SE) magnetic resonance (MR) imaging in the differentiation of fibrosis from tumor recurrence during the follow-up of treated gynecologic pelvic malignancy.
MATERIALS AND METHODS: Thirty-four patients (aged 24-82 years) with 18 benign and 35 malignant lesions confirmed by means of surgery (n = 18), biopsy (n = 25), or 18-month follow-up examination (n = 10) underwent dynamic contrast-enhanced subtraction and T2-weighted SE MR imaging. Contrast material enhancement of an abnormal pelvic structure within the first 90 seconds on dynamic contrast-enhanced subtraction images or high signal intensity on T2-weighted SE images was considered indicative of malignancy.
RESULTS: The sensitivity, specificity, accuracy, and positive and negative predictive values were 91%, 67%, 83%, 86%, and 86%, respectively, for dynamic contrast-enhanced subtraction imaging and 91%, 22%, 68%, 70%, and 57%, respectively, for T2-weighted SE imaging. More lesions were correctly classified with dynamic contrast-enhanced subtraction imaging than with T2-weighted SE imaging (P < .01).
CONCLUSION: Dynamic contrast-enhanced subtraction imaging is more accurate than T2-weighted SE imaging for differentiating fibrosis from tumor recurrence during the follow-up of treated gynecologic pelvic malignancy. However, use of both sequences is recommended.

Entities:  

Mesh:

Year:  1997        PMID: 9205223     DOI: 10.1148/radiology.204.1.9205223

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  25 in total

1.  Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology.

Authors:  Corinne Balleyguier; E Sala; T Da Cunha; A Bergman; B Brkljacic; F Danza; R Forstner; B Hamm; R Kubik-Huch; C Lopez; R Manfredi; J McHugo; L Oleaga; K Togashi; K Kinkel
Journal:  Eur Radiol       Date:  2010-11-10       Impact factor: 5.315

2.  Cervical cancer: MR imaging findings before, during, and after radiation therapy.

Authors:  Gulgun Engin
Journal:  Eur Radiol       Date:  2005-06-14       Impact factor: 5.315

Review 3.  Role of MR Imaging and FDG PET/CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic Malignancies.

Authors:  Yulia Lakhman; Stephanie Nougaret; Maura Miccò; Chiara Scelzo; Hebert A Vargas; Ramon E Sosa; Elizabeth J Sutton; Dennis S Chi; Hedvig Hricak; Evis Sala
Journal:  Radiographics       Date:  2015 Jul-Aug       Impact factor: 5.333

4.  Pelvic imaging following chemotherapy and radiation therapy for gynecologic malignancies.

Authors:  Helen C Addley; Hebert Alberto Vargas; Penelope L Moyle; Robin Crawford; Evis Sala
Journal:  Radiographics       Date:  2010-11       Impact factor: 5.333

5.  Detection of Local Recurrence in Patients with Head and Neck Squamous Cell Carcinoma Using Voxel-Based Color Maps of Initial and Final Area under the Curve Values Derived from DCE-MRI.

Authors:  J Y Lee; K L Cheng; J H Lee; Y J Choi; H W Kim; Y S Sung; S R Chung; K H Ryu; M S Chung; S Y Kim; S-W Lee; J H Baek
Journal:  AJNR Am J Neuroradiol       Date:  2019-07-18       Impact factor: 3.825

Review 6.  Primary vaginal cancer: role of MRI in diagnosis, staging and treatment.

Authors:  C S Gardner; J Sunil; A H Klopp; C E Devine; T Sagebiel; C Viswanathan; P R Bhosale
Journal:  Br J Radiol       Date:  2015-05-12       Impact factor: 3.039

7.  Prediction of disease progression following concurrent chemoradiotherapy for uterine cervical cancer: value of post-treatment diffusion-weighted imaging.

Authors:  Jung Jae Park; Chan Kyo Kim; Byung Kwan Park
Journal:  Eur Radiol       Date:  2015-12-18       Impact factor: 5.315

8.  Real-time tissue sonoelastography for early response monitoring in cervical cancer patients treated with definitive chemoradiotherapy: preliminary results.

Authors:  Seiji Mabuchi; Tomoyuki Sasano; Hiromasa Kuroda; Ryoko Takahashi; Satoshi Nakagawa; Tadashi Kimura
Journal:  J Med Ultrason (2001)       Date:  2015-02-13       Impact factor: 1.314

9.  Treatment options in recurrent cervical cancer (Review).

Authors:  Angiolo Gadducci; Roberta Tana; Stefania Cosio; Luca Cionini
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

Review 10.  Ovarian cancer: the clinical role of US, CT, and MRI.

Authors:  Kaori Togashi
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.